Domperidone is avoided in patients with cardiac disease because it prolongs the QT interval and significantly increases the risk of life-threatening ventricular arrhythmias and sudden cardiac death.
The primary cardiac concern with domperidone is QT prolongation leading to torsades de pointes and sudden cardiac death, with risk increasing 70% compared to non-use, particularly in patients with pre-existing cardiac conditions. 1, 2, 3, 4
Mechanism of Cardiac Risk
Domperidone acts as a potent hERG potassium channel blocker at clinically relevant concentrations, which directly prolongs cardiac repolarization and the QT interval 5. This mechanism creates electrical instability in the heart that can trigger:
- Torsades de pointes (polymorphic ventricular tachycardia)
- Ventricular arrhythmias
- Sudden cardiac death
The drug causes action potential prolongation and triangulation—both markers of proarrhythmic potential 5.
Evidence of Cardiovascular Risk
Multiple meta-analyses demonstrate consistent findings:
- Pooled adjusted odds ratio of 1.69-1.70 for sudden cardiac death or ventricular arrhythmia compared to non-use 3, 4
- Risk increases to 11-fold with doses >30 mg/day 6
- The evidence quality is moderate with homogeneous findings across studies (I² = 0%) 3, 4
The 2006 ACC/AHA/ESC guidelines specifically list domperidone among antiemetics that cause QT prolongation, alongside droperidol 2. The 2017 JACC cardio-oncology guidelines identify domperidone as one of the most common drugs causing QTc prolongation when used with other medications 7.
Specific Cardiac Contraindications
Absolute contraindications include 1, 5:
- Pre-existing QT prolongation or congenital long QT syndrome
- Baseline QTc >440 ms (or >500 ms with ventricular conduction delay)
- History of ventricular arrhythmias
- Structural heart disease (heart failure, cardiomyopathy)
- Significant electrolyte abnormalities (hypokalemia, hypomagnesemia)
- Concurrent use of CYP3A4 inhibitors (erythromycin, ketoconazole) which can cause multi-fold increases in domperidone exposure 1
High-Risk Patient Populations
Risk factors that amplify cardiac danger 2, 6:
- Age >60 years (significantly increased risk)
- Female gender
- Bradycardia or heart block
- Congestive heart failure
- Digitalis therapy
- Recent conversion from atrial fibrillation
- Concomitant QT-prolonging medications (ondansetron, antipsychotics, certain antibiotics)
Required Monitoring Protocol
The 2025 AGA gastroparesis guidelines mandate strict cardiac surveillance if domperidone is used 1:
Before initiating:
- Baseline ECG with QTc measurement
- Serum potassium and magnesium levels
- Accurate assessment of renal function
During treatment:
- Continuous monitoring of serum potassium and magnesium
- Serial ECG monitoring of QTc interval
- Assessment at 4-8 weeks to determine continuation
- Immediate discontinuation if QTc >500 ms
Clinical Context and Alternatives
The AGA conditionally recommends against domperidone as first-line treatment for gastroparesis (very low quality evidence) 1. It may be reserved for patients who:
- Failed or cannot tolerate metoclopramide due to neurologic side effects
- Have Parkinson's disease (where metoclopramide is contraindicated)
- Explicitly decline metoclopramide after shared decision-making
Critical caveat: Domperidone is not FDA-approved in the United States and requires an expanded access investigational new drug (IND) application 1. The current U.S. supplier is exiting the market, making access increasingly limited.
Comparison with Other Prokinetics
While metoclopramide carries neurologic risks (tardive dyskinesia), it does not share domperidone's cardiac toxicity profile. The 2022 ESC polypharmacy guidelines and 2017 cardio-oncology guidelines emphasize avoiding domperidone in elderly patients and those with cardiovascular disease 7, 8.
The fundamental issue is that domperidone's cardiac risks—particularly in patients with any cardiac disease—outweigh its gastrointestinal benefits, making it contraindicated in this population.